Marina inks $14M discovery pact with ProNAi

Bothell, WA-based Marina Biotech will put its Smarticles liposomal delivery technology to work for ProNAi Therapeutics in a discovery pact revolving around DNAi-based therapeutics. Marina Biotech stands to gain up to $14 million for each gene target in total upfront, clinical and commercialization milestone payments, as well as royalties. ProNAi will have the option to select any number of additional gene targets. Release

 

Suggested Articles

The deal gives J&J a stake in the development and commercialization of anticoagulants including phase 2-ready secondary stroke candidate BMS-986177.

Boehringer gained the global rights to OSE's SIRP-alpha antagonist, which is in development for solid tumors.

Lilly is diving into encapsulated beta cell treatments, designed to restore insulin production in patients with Type 1 diabetes.